RYTM
NASD Rhythm Pharmaceuticals, Inc.$92.45 ↑ +0.00 (+0.00%) Trading Up from the previous close of $92.45, $1.96 below the day’s high of $94.41
- YTD change
- -13.63%
- vs 20-day SMA
- -6.40%
- vs 200-day SMA
- -6.51%
Price ranges
Price & Performance
+5.49 (+6.31%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 24.3% away from all-time highs of $122.20
- RYTM is down 14% since the beginning of the year
- RYTM is down 7% over the past 12 months
- RYTM is down 12% over the past 1 month
- 15% of all RYTM investors are betting against RYTM
RYTM reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -5.5%.
- Previous minute
- +$0.00
- Last hour
- -$1.45
- Last 5 days
- -6.29%
- vs 8-day SMA
- -4.06%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
